Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study
Second-gen ALK inhibitor induces high response rate, associated with impressive survival
David Sibon Henri Mondor University Hospital In Cr French Lymphoma Study Association Henri Mondor University Hospital New England Journal French Lymphoma Study
Source: medpagetoday.com